Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative price increase of over 20% in the next six months [15]. Core Insights - The company is enhancing its universal CAR-T product portfolio, with the in vivo CAR-T expected to initiate clinical trials in 2026. The proprietary platforms, THANK-uCAR® and THANK-u Plus®TM, are being utilized to develop differentiated universal CAR-T cell products [2][3]. - The company reported a revenue of 1.3 billion yuan in 2025, with a net loss of 1 billion yuan, a significant reduction from the previous year's loss of 8 billion yuan. As of December 31, 2025, cash and cash equivalents stood at 1.12 billion yuan [8]. - The company has received 218 orders for its product, Sikeizai®, from East China Pharmaceutical in 2025 and has been included in the "Commercial Health Insurance Innovative Drug Directory" [8]. Financial Projections - Revenue projections for the company are as follows: 2.6 billion yuan in 2026, 4.9 billion yuan in 2027, and 8 billion yuan in 2028, driven by the commercialization of CT053 and CT041 [10][11]. - The company anticipates a significant increase in net profit, projecting a profit of 63.26 million yuan in 2027 and 249.58 million yuan in 2028, following a net loss of 97.86 million yuan in 2025 [3][11]. - Earnings per share (EPS) are expected to improve from -0.17 yuan in 2025 to 0.43 yuan in 2028, reflecting the anticipated growth in profitability [3][11]. Product Development - The company is advancing multiple universal CAR-T products targeting various antigens, including CT0596 (BCMA) and CT1190B (CD19/CD20), with initial data expected to be presented at the ASH conference in December 2025 [2]. - The in vivo CAR-T candidate, KJ-C2529, targeting CD19/CD20 for B-cell lymphoma, is set to begin clinical trials in 2026 [2].